Jayakumar Edathedathe Krishnan1, Noushad Thekke Puthiyottil2, Sreelatha Melemadathil3
The aim of this retrospective study was to compare therapeutic efficacy and safety profile of Cyclosporin and Tacrolimus in post-transplant patients with respect to graft function and metabolic disorders.
MATERIALS AND METHODS
Data of patients who underwent renal transplant in Calicut Medical College during July 2014 to December 2015 was collected and baseline parameters like BP, Blood glucose, cholesterol, RFT and LFT levels were assessed at 2 weeks, 1 month, 6 months and at 1 year in one year completed subgroup. Incidence of delayed graft function and acute rejection were also included.
Clinical data of 60 patients (32 in Cyclosporin group and 28 in Tacrolimus group) were collected. Among the 60 patients, 32 patients (16 in Cyclosporin group and 16 in Tacrolimus group) completed one year. The incidence of acute rejection with Cyclosporin group and with Tacrolimus group was 14.7% and 13.6% and 31.2% and 25% at 6 months and 1 year respectively. At one year in the subgroup for 32 patients, serum creatinine was <1.2 mg/dL in 75% Cyclosporin group and 80.5% in Tacrolimus group. After 1 year, Hb>17 was seen in 6.25% (1/16) in Cyclosporin group and none in Tacrolimus group. Dyslipidaemia was observed in 56.3% (9/16) in Cyclosporin group and 32.5% (6/16) in Tacrolimus group. At one year, hirsutism was 18.7% with Cyclosporin group and 0% with Tacrolimus group.
No statistically significant difference in graft function & incidence of acute rejection between the two treatment groups at 6 months & 1 year.